Tubulis Recognized as One of 2024’s “Fierce 15” Biotechnology Companies by Fierce Biotech

Tubulis Recognized as One of 2024’s “Fierce 15” Biotechnology Companies by Fierce Biotech

(IN BRIEF) Tubulis has been named one of 2024’s “Fierce 15” biotechnology companies by Fierce Biotech. This recognition celebrates Tubulis’ innovative work in ADC development and its commitment to improving cancer treatment outcomes. With significant recent advancements, including a €128 million Series B2 financing and the initiation of clinical trials for lead candidates, Tubulis is poised to make substantial impacts in the biotech field.

(PRESS RELEASE) MUNICH, 6-Aug-2024 — /EuropaWire/ — Tubulis has been named one of 2024’s “Fierce 15” biotechnology companies by Fierce Biotech, an annual accolade recognizing the most innovative and promising biotech firms in the industry.

Dominik Schumacher, CEO of Tubulis, expressed pride in receiving this prestigious award, stating, “This recognition underscores our leadership in the ADC space and highlights the potential of our unique approach to ADC development. It is a testament to the hard work and dedication of our team and Board. 2024 is a pivotal year for us, and we are committed to advancing the boundaries of ADCs to unlock their full therapeutic potential.”

Tubulis is dedicated to enhancing the performance of Antibody-Drug Conjugates (ADCs) by innovating across all aspects of their development. The company’s suite of technologies integrates diverse targeting molecules, innovative payloads, and proprietary conjugation methods to create ADCs with superior biophysical properties and durable anti-tumor effects. With promising preclinical results and a significant €128 million Series B2 financing in March, Tubulis is now advancing its lead candidates, TUB-030 and TUB-040, into clinical trials.

In June, Tubulis dosed the first patient in a Phase I/IIa study (NAPISTAR 1-01, NCT06303505) for TUB-040, investigating its safety, pharmacokinetics, and efficacy in patients with platinum-resistant high-grade ovarian cancer (PROC) and relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC). The U.S. FDA granted Fast Track designation to TUB-040 for treating PROC shortly after.

Ayla Ellison, Editor-in-Chief of Fierce Life Sciences and Healthcare, noted the rigorous selection process for the “Fierce 15,” which evaluates companies based on technological innovation, strategic partnerships, venture support, and market positioning. “This report highlights innovation and creativity amid intense competition,” Ellison said.

About Tubulis

Tubulis’ suite of proprietary platform technologies generates uniquely matched antibody-drug conjugates with superior biophysical properties for treating solid tumors. By demonstrating durable on-tumor delivery of the payload and long-lasting anti-tumor activity, we have reached the clinic with our first program, TUB-040, in ovarian and non-small cell lung cancer. The second candidate from our growing pipeline, TUB-030, is set to follow in the near-term. We will solidify our leadership position by continuing to innovate on all aspects of ADC design to expand their therapeutic potential for our pipeline, our partners and for patients. Visit www.tubulis.com or follow us on LinkedIn.

About Fierce Biotech

Fierce Biotech is the biotech industry’s daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day’s top stories.

Media Contact:

Dominik Schumacher
CEO & Co-Founder
Phone: +49 175 800 5594
Email: contact@tubulis.com

Stephanie May or Marie Weickert
Trophic Communications
Phone: + 49 171 185 5682
Email: tubulis@trophic.eu

SOURCE: Tubulis GmbH